Press Release: Small Pharma Announces Significant Developments In Intellectual Property Portfolio

Small Pharma Inc.
Small Pharma Inc.

5 new patent grants, 3 expected upcoming patent grants, and 8 notices of allowance in key international jurisdictions

LONDON, May 25, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectual property (“IP“) portfolio, demonstrating significant progress already made by the Company in 2023.

Small Pharma aims to protect its pipeline programs through a multi-layered IP strategy with four core areas of protection. These areas of protection include: Composition of Matter, covering novel drug substances; Medical Use, covering therapeutic compositions and medical uses thereof; Drug Product, covering pharmaceutical formulations; and Synthetic Route, covering the novel and efficient synthesis of high purity drug substance at scale.

Since the previous IP portfolio update on February 1, 2023, the Company has secured five new granted patents, with three more expected to be granted by May 31, 2023. Additionally, it has received five patent Notices of Allowance. The additional IP covers the four focused areas of protection and multiple markets, strengthening the Company’s international IP position.

The new patent grants and Notices of Allowance are summarized below.

Patent
Protection
Description Market Patent No. Status
Composition of
Matter 
For certain deuterated homologues of certain tryptamine compounds USA 11,578,039 Granted
For certain deuterated homologues of certain tryptamine compounds New
Zealand
788543 Granted
For certain deuterated analogues of N,N, dimethyltryptamine (“DMT”) GB 2 592 822 Grant expected
after May 22, 2023
For a group of deuterated homologues of DMT USA 11,660,289 Grant expected on
May 30, 2023
For a group of deuterated homologues of DMT Europe 4 031 529 Notice of
Allowance
Medical Use Of certain deuterated analogues of DMT GB 2 586 940 Grant expected
after May 25, 2023
Medical use and therapeutic compositions of a group of deuterated homologues of DMT Australia 2021204158 Notice of
Allowance
Medical use and therapeutic compositions of a group of deuterated homologues of DMT New Zealand 794833 Notice of
Allowance
Therapeutic compositions of a group of deuterated homologues of DMT Japan 2022-574099 Notice of
Allowance
Drug Product Novel optimized injectable formulation of DMT based compounds Australia 2021334933 Granted
Therapeutic solid dosage forms of deuterated DMT analogues GB 2 595 776 Granted
Synthetic Route  Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scale USA 11,643,390 Granted
Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scale Canada 3160337 Notice of
Allowance

As of May 24, 2023, Small Pharma’s IP portfolio consists of 19 granted patents, with 97 allowed or pending. The protection covering each of the Company’s pipeline programs is outlined below.

Primary Sponsor

 


Karma Koala Podcast

Top Marijuana Blog